Aradigm : Phase 2 Data with Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis

June 30, 2008 - Aradigm Corporation (OTCBB:ARDM) (the Company) announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF). The study conducted at leading CF centers in Australia and New Zealand enrolled a total of 22 patients.
The primary efficacy endpoint in this Phase 2 study was the change from baseline in the sputum Pseudomonas Aeruginosa colony forming units (CFU), an objective measure of the reduction in pulmonary bacterial load... Aradigm's Press Release -

Aradigm : Phase 2 Study of Inhaled Liposomal Ciprofloxacin in Bronchiectasis

June 19, 2008- Study Will Explore New Treatment of a Severe Respiratory Disease Condition with Unmet Medical Need -Aradigm Corporation (OTCBB: ARDM) (the "Company") announced it has initiated a multicenter Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.

Following an antibiotic washout period, 36 patients will be enrolled to receive daily inhaled liposomal ciprofloxacin for a period of 28 consecutive days. The primary efficacy endpoint will be treatment of respiratory infection measured as the change in the density of Pseudomonas Aeruginosa bacterial colony forming units (CFU) in the sputum over the treatment period. Secondary endpoints will include pulmonary function measurements and respiratory symptoms. The study is being conducted in leading bronchiectasis centers in the United Kingdom... Aradigm's Press Release -

Aradigm : Trial of Lung Rx's Inhaled Treprostinil

April 8, 2008--Aradigm Corporation (OTCBB: ARDM) announced it initiated a bridging clinical trial of inhaled treprostinil utilizing its AERx Essence(R) pulmonary delivery system. The trial in healthy volunteers is being conducted in the United Kingdom to evaluate aerosol delivery by assessing lung distribution, pharmacokinetics and safety of inhaled treprostinil delivered by the AERx Essence system versus delivery with the Nebu-Tec OPTINEB*-ir nebulizer.
The latter device was used by Lung Rx, Inc. (Lung Rx), a wholly owned subsidiary of United Therapeutics Corporation, in the recently concluded TRIUMPH (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) study of inhaled treprostinil in patients with Pulmonary Arterial Hypertension (PAH)... Aradigm's Press Release -

Aradigm and CyDex, Development Collaboration Agreement for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

September 6, 2007 - Aradigm Corporation (OTCBB:ARDM) and CyDex, Inc. ("CyDex") have entered into a two-year Collaboration Agreement for the development and commercialization of combination products containing inhaled corticosteroids, anticholinergics and beta-2 agonists for the treatment of asthma and chronic obstructive pulmonary diseases (COPD)... Press Release -